These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 29748897)

  • 21. Mathematical Analysis of Cytokine-Induced Differentiation of Granulocyte-Monocyte Progenitor Cells.
    Weston BR; Li L; Tyson JJ
    Front Immunol; 2018; 9():2048. PubMed ID: 30279691
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Treatment of chemotherapy-induced neutropenia pegylated recombinant human granulocyte colony-stimulating factor: a multi-center randomized controlled phase II clinical study].
    Shi YK; He XH; Yang S; Wang HQ; Jiang ZF; Zhu YZ; Ke XY; Zhang Y; Liu YP; Zhang WJ; Wang Z; Shi QZ; Xie XD; Zhang HL; Wang JJ; Luo DY; Zheng QS; Sun RY
    Zhonghua Yi Xue Za Zhi; 2006 Dec; 86(48):3414-9. PubMed ID: 17313855
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tracking the fate of adoptively transferred myeloid-derived suppressor cells in the primary breast tumor microenvironment.
    Sceneay J; Griessinger CM; Hoffmann SHL; Wen SW; Wong CSF; Krumeich S; Kneilling M; Pichler BJ; Möller A
    PLoS One; 2018; 13(4):e0196040. PubMed ID: 29677215
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Graft monocytic myeloid-derived suppressor cell content predicts the risk of acute graft-versus-host disease after allogeneic transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood stem cells.
    Vendramin A; Gimondi S; Bermema A; Longoni P; Rizzitano S; Corradini P; Carniti C
    Biol Blood Marrow Transplant; 2014 Dec; 20(12):2049-55. PubMed ID: 25246295
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Graft-Versus-Host Disease Prevention by
    Scheurer J; Kitt K; Huber HJ; Fundel-Clemens K; Pflanz S; Debatin KM; Strauss G
    Front Immunol; 2021; 12():754316. PubMed ID: 34721430
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MDSCs are involved in the protumorigenic potentials of GM-CSF in colitis-associated cancer.
    Ma N; Liu Q; Hou L; Wang Y; Liu Z
    Int J Immunopathol Pharmacol; 2017 Jun; 30(2):152-162. PubMed ID: 28534709
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Granulocytic myeloid-derived suppressor cells promote angiogenesis in the context of multiple myeloma.
    Binsfeld M; Muller J; Lamour V; De Veirman K; De Raeve H; Bellahcène A; Van Valckenborgh E; Baron F; Beguin Y; Caers J; Heusschen R
    Oncotarget; 2016 Jun; 7(25):37931-37943. PubMed ID: 27177328
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting myeloid-derived suppressor cells for cancer immunotherapy.
    Liu Y; Wei G; Cheng WA; Dong Z; Sun H; Lee VY; Cha SC; Smith DL; Kwak LW; Qin H
    Cancer Immunol Immunother; 2018 Aug; 67(8):1181-1195. PubMed ID: 29855694
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunosuppressive effects and mechanisms of three myeloid-derived suppressor cells subsets including monocytic-myeloid-derived suppressor cells, granulocytic-myeloid-derived suppressor cells, and immature-myeloid-derived suppressor cells.
    Nagatani Y; Funakoshi Y; Suto H; Imamura Y; Toyoda M; Kiyota N; Yamashita K; Minami H
    J Cancer Res Ther; 2021; 17(4):1093-1100. PubMed ID: 34528569
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Granulocyte Colony-Stimulating Factor Attenuates Renal Ischemia-Reperfusion Injury by Inducing Myeloid-Derived Suppressor Cells.
    Yan JJ; Ryu JH; Piao H; Hwang JH; Han D; Lee SK; Jang JY; Lee J; Koo TY; Yang J
    J Am Soc Nephrol; 2020 Apr; 31(4):731-746. PubMed ID: 32132198
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunomodulatory effects of myeloid-derived suppressor cells in diseases: Role in cancer and infections.
    Tamadaho RSE; Hoerauf A; Layland LE
    Immunobiology; 2018; 223(4-5):432-442. PubMed ID: 29246400
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circulating Myeloid-Derived Suppressor Cell Subsets in Patients with Colorectal Cancer - Exploratory Analysis of Their Biomarker Potential.
    Fědorová L; Pilátová K; Selingerová I; Bencsiková B; Budinská E; Zwinsová B; Brychtová V; Langrová M; Šefr R; Valík D; Zdražilová Dubská L
    Klin Onkol; 2018; 31(Suppl 2):88-92. PubMed ID: 31023030
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glutamine Deprivation Promotes the Generation and Mobilization of MDSCs by Enhancing Expression of G-CSF and GM-CSF.
    Sun HW; Wu WC; Chen HT; Xu YT; Yang YY; Chen J; Yu XJ; Wang Z; Shuang ZY; Zheng L
    Front Immunol; 2020; 11():616367. PubMed ID: 33603745
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized controlled clinical trial of polyethylene glycol recombinant human granulocyte colony-stimulating factor in the treatment of neutropenia after chemotherapy for breast cancer.
    Huang W; Liu J; Zeng Y; Wu F; Li N; Chen K; Hong Y; Wang L; Zhen H; Lin L
    Cancer Chemother Pharmacol; 2018 Oct; 82(4):607-613. PubMed ID: 30043207
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monocytic and promyelocytic myeloid-derived suppressor cells may contribute to G-CSF-induced immune tolerance in haplo-identical allogeneic hematopoietic stem cell transplantation.
    Lv M; Zhao XS; Hu Y; Chang YJ; Zhao XY; Kong Y; Zhang XH; Xu LP; Liu KY; Huang XJ
    Am J Hematol; 2015 Jan; 90(1):E9-E16. PubMed ID: 25303038
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Understanding the Differentiation, Expansion, Recruitment and Suppressive Activities of Myeloid-Derived Suppressor Cells in Cancers.
    Lim HX; Kim TS; Poh CL
    Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32443699
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Granulocyte colony-stimulating factors as prophylaxis against febrile neutropenia.
    Cortés de Miguel S; Calleja-Hernández MÁ; Menjón-Beltrán S; Vallejo-Rodríguez I
    Support Care Cancer; 2015 Feb; 23(2):547-59. PubMed ID: 25284722
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Granulocytic myeloid-derived suppressor cells maintain feto-maternal tolerance by inducing Foxp3 expression in CD4+CD25-T cells by activation of the TGF-β/β-catenin pathway.
    Kang X; Zhang X; Liu Z; Xu H; Wang T; He L; Zhao A
    Mol Hum Reprod; 2016 Jul; 22(7):499-511. PubMed ID: 27016139
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mathematical modeling of tumor-induced immunosuppression by myeloid-derived suppressor cells: Implications for therapeutic targeting strategies.
    Shariatpanahi SP; Shariatpanahi SP; Madjidzadeh K; Hassan M; Abedi-Valugerdi M
    J Theor Biol; 2018 Apr; 442():1-10. PubMed ID: 29337259
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
    Wong SF; Chan HO
    Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.